Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06468202 · ClinicalTrials.gov registry record · Phase 4

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

A Phase 4 study of Preeclampsia and Gestational Hypertension, sponsored by Ohio State University.

Recruiting
Registry status
Phase 4
Development phase
10,742
Enrollment target
16
Study locations

NCT06468202 is a Phase 4 study of Preeclampsia and Gestational Hypertension that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 10,742 participants, above the 1,007-participant average among 39 other Preeclampsia trials with a reported enrollment target (967% higher). The trial reports 16 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06468202, a Phase 4 study of Preeclampsia and Gestational Hypertension, is actively recruiting participants, sponsored by Ohio State University.

RECRUITING
Registry status
Phase 4
Development phase
10,742 participants
Enrollment target
16
Study locations

Study Summary

The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.

Conditions Studied

Preeclampsia Gestational Hypertension Hypertensive Disorders of Pregnancy

Interventions

  • DRUG Aspirin 162 mg
  • DRUG Aspirin 81 mg

Study Locations (16)

California

  • Cedars Sinai Medical Center - Los Angeles
  • University of California, San Francisco - San Francisco

Virginia

  • Inova HealthSystem - Falls Church
  • Eastern Virginia Medical School - Old Dominion University - Norfolk

Alabama

  • University of Alabama at Birmingham - Birmingham

Illinois

  • Northwestern University - Chicago

Mississippi

  • University of Mississippi - Jackson

New Mexico

  • University of New Mexico - Albuquerque

New York

  • Columbia University - New York

North Carolina

  • University of North Carolina, Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 10,742 participants
Start Date 2024-10-18
Est. Completion 2030-02-01
Phase Phase 4

Sponsor

Ohio State University

552 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06468202

The ClinicalTrials.gov registry entry for NCT06468202 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 10,742 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,007-participant average among 39 other Preeclampsia trials with a reported enrollment target (967% higher). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Aspirin 162 mg is the first listed.

NCT06468202 reports 16 study locations spanning 14 distinct geographic areas - top geographies include California, Virginia, Alabama.

Frequently Asked Questions

What is clinical trial NCT06468202 about?

NCT06468202 is a clinical study titled "Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL". The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with...

What is the current status of trial NCT06468202?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10,742 participants. The study started on 2024-10-18. Estimated completion is 2030-02-01.

What conditions does trial NCT06468202 study?

This clinical trial studies the following conditions: Preeclampsia, Gestational Hypertension, Hypertensive Disorders of Pregnancy.

What interventions are being tested in trial NCT06468202?

The interventions under investigation include: Aspirin 162 mg (DRUG), Aspirin 81 mg (DRUG).

Who is sponsoring clinical trial NCT06468202?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06468202 being conducted?

This trial has 16 study locations across Alabama, California, Illinois, Mississippi, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Preeclampsia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Preeclampsia

All registered trials for this condition

Gestational Hypertension

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.